Buzz: GSK plots board coup in HGS flank attack

Forget the usual thin-end-of-the-wedge proxy-fight strategy. Rather than nominating a few directors to push its buyout agenda at Human Genome Sciences ($HGSI), GlaxoSmithKline ($GSK) plans a campaign to sweep the whole board out, Reuters reports. That would clear the way for its $2.6 billion hostile bid. Report


Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.